GlobeNewswire by notified

Buy-backs of shares in CoinShares International Limited

Share

19 January 2023 | SAINT HELIER, Jersey - As announced on 30 December 2022, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's largest and leading digital asset investment and trading group, resolved to implement a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 3 January 2023, up to and including 3 April 2023 for total maximum amount of SEK 25 million in accordance with the authorisation from the Annual General Meeting on 20 June 2022.

The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company.

The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").

The Company today announces that share buy-backs of shares in the Company (ISIN: JE00BLD8Y945) have been effected as set forth below (aggregated level):

DateNumber of shares acquiredLowest price paid (SEK)Highest price paid (SEK)Volume weighted average (SEK)
12 January 2023 3,695 21.90 22.65 22.42
13 January 2023 2,986 23.00 23.55 23.41
18 January 2023 2,283 24.95 25.45 25.23
8,964

All share buy-backs have been carried out on Nasdaq Stockholm Market by the Company. Following the above repurchases, the Company's holding of own shares as of 19 January 2023 amounts to 217,495 shares. The total number of shares in CoinShares amounts to 68,135,425.

For a full break-down of repurchases made, please refer to the attached announcement.

About CoinShares

CoinShares is Europe’s largest and leading digital asset investment and trading group, managing billions of assets on behalf of a global client base. Our mission is to expand investing into digital assets with our trusted, regulated, best-in-class product suite that provides investors with trust and transparency when accessing cryptocurrencies. We believe that Bitcoin and blockchain networks are landmark innovations that will fundamentally reshape the global financial system and the way we interact digitally, and investors should be able to participate in this transformation. CoinShares is publicly listed on the Nasdaq Stockholm under ticker CS and the OTCQX under the ticker CNSRF. CoinShares has multiple touchpoints with financial regulatory bodies around the world, including the AMF, JFSC and FINRA.

For more information on CoinShares, please visit: https://coinshares.com
Company | +44 (0)1534 513 100 | enquiries@coinshares.com
Investor Relations | +44 (0)1534 513 100 | enquiries@coinshares.com

This information is information that CoinShares International Limited is obliged to make public pursuant to the EU Market Abuse Regulation (596/2014). The information in this press release has been published through the agency of the contact persons set out above, at 08:00 GMT on Thursday, 19 January 2023.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

Nokia Corporation: Repurchase of own shares on 07.05.20247.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 07 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 07.05.2024 Espoo, Finland – On 07 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL376,2023.48CEUX--BATE--AQEU--TQEX--Total376,2023.48 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye